Author/Authors :
Ferreira Vinicius Lins نويسنده Department of Pharmacy, Pharmaceutical Sciences
Postgraduate Program, Universidade Federal do Parana, Curitiba,
Brazil , Souza Vanessa Rodrigues de نويسنده Department of Pharmacy, Pharmaceutical Sciences
Postgraduate Program, Universidade Federal do Parana, Curitiba,
Brazil , Araujo Muzzillo Dominique نويسنده Department of Internal Medicine, Hospital de Clinicas,
Universidade Federal do Parana, Curitiba, Brazil , Pontarolo Roberto نويسنده Department of Pharmacy, Pharmaceutical Sciences
Postgraduate Program, Universidade Federal do Parana, Curitiba,
Brazil
Abstract :
Context Hepatitis E virus (HEV) is well-known to be transmitted by
the fecal-oral route. In addition, several studies in Europe and Asia
had reported potential HEV transmission associated with blood
transfusion, but this route is still uncertain. Objective The aim of
this study was to estimate the anti-HEV IgG seroprevalence among blood
donors around the world using the Bayesian-based methods. Evidence
Acquisition A systematic review was performed using the PubMed/Medline,
Scopus, Web of Science and Cochrane Library databases using the terms
“prevalence”, “hepatitis E” and “blood donors”. Studies with a timeframe
from inception to March 2016, in Roman characters, that had outcomes of
interest such as prevalence of IgG antibodies were included. The
estimation of anti-HEV IgG (presented as the event rate and 95%
confidence intervals, CI) was performed using a Bayesian-based random
effect model using the Comprehensive Meta-Analysis software, version 2.
Pairwise meta-analyses and chi-square tests were used to assess
significant differences between different sexes and ages. Results and
Conclusions Of the retrieved studies, 71 met the inclusion criteria,
comprising a total of 113 316 blood donors. The prevalence rate was
statistically significant in males and over 40 years old donors (P
< 0.05). The overall estimation of the anti-HEV IgG prevalence
was 0.058 (CI 95%: 0.049 - 0.068). Subgrouping by region, the estimates
were higher for Asia and the Middle East, respectively: 0.113 (CI 95%:
0.040 - 0.278) and 0.112 (CI 95%: 0.081 - 0.152). Europe, Africa,
Oceania and America had an estimated prevalence between 0.014and 0.088.
A relevant prevalence of anti-HEV IgG among blood donors was found
worldwide, especially in Asia and the Middle East and in males and
donors over 40 years. This review reinforces the view that HEV
parenteral route infection needs to be further investigated and possibly
screened for in transfused blood.
